S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play
Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company
Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy
In duel with small investors over GameStop, big funds blink
Stocks have their worst day since October as Big Tech sinks
AP sources: Biden to pause oil and gas sales on public lands
In battle over GameStop shares, two big players flinch
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play
Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company
Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy
In duel with small investors over GameStop, big funds blink
Stocks have their worst day since October as Big Tech sinks
AP sources: Biden to pause oil and gas sales on public lands
In battle over GameStop shares, two big players flinch
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play
Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company
Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy
In duel with small investors over GameStop, big funds blink
Stocks have their worst day since October as Big Tech sinks
AP sources: Biden to pause oil and gas sales on public lands
In battle over GameStop shares, two big players flinch
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play
Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company
Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy
In duel with small investors over GameStop, big funds blink
Stocks have their worst day since October as Big Tech sinks
AP sources: Biden to pause oil and gas sales on public lands
In battle over GameStop shares, two big players flinch
Log in
ASX:FTT

Factor Therapeutics Limited (FTT.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume425,600 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Factor Therapeutics Limited operates as a clinical stage biotechnology company. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. Factor Therapeutics Limited is based in Brisbane, Australia.

MarketRank™

Overall MarketRank™

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:FTT
Previous SymbolASX:TIS
CUSIPN/A
CIKN/A
Webfactor-therapeutics.com
Phone+61-7-33343900
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio83.12
Quick Ratio81.35

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$665,817.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow1.00
Book ValueA$0.00 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive FTT News and Ratings via Email

Sign-up to receive the latest news and ratings for FTT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Factor Therapeutics Limited (FTT.AX) (ASX:FTT) Frequently Asked Questions

What stocks does MarketBeat like better than Factor Therapeutics Limited (FTT.AX)?

Wall Street analysts have given Factor Therapeutics Limited (FTT.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Factor Therapeutics Limited (FTT.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Factor Therapeutics Limited (FTT.AX)'s earnings last quarter?

Factor Therapeutics Limited (FTT.AX) (ASX:FTT) announced its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter.
View Factor Therapeutics Limited (FTT.AX)'s earnings history.

Who are some of Factor Therapeutics Limited (FTT.AX)'s key competitors?

Some companies that are related to Factor Therapeutics Limited (FTT.AX) include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Algernon Pharmaceuticals (AGNPF).
View all of FTT's competitors.

Who are Factor Therapeutics Limited (FTT.AX)'s key executives?

Factor Therapeutics Limited (FTT.AX)'s management team includes the following people:
  • Ms. Melanie Farris M.A.I.C.D., ACIS) BComn, (AGIA, GradDip, ACG, Company Sec.

What is Factor Therapeutics Limited (FTT.AX)'s stock symbol?

Factor Therapeutics Limited (FTT.AX) trades on the ASX under the ticker symbol "FTT."

How big of a company is Factor Therapeutics Limited (FTT.AX)?

Factor Therapeutics Limited (FTT.AX) has a market capitalization of $0.00 and generates $665,817.00 in revenue each year.

What is Factor Therapeutics Limited (FTT.AX)'s official website?

The official website for Factor Therapeutics Limited (FTT.AX) is factor-therapeutics.com.

How can I contact Factor Therapeutics Limited (FTT.AX)?

Factor Therapeutics Limited (FTT.AX)'s mailing address is L 19 179 Turbot St, BRISBANE, QLD 4000, Australia. The biotechnology company can be reached via phone at +61-7-33343900.

This page was last updated on 1/28/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.